Thalidomide modulation of the immune response in female B6C3F1 mice: A host resistance study

International Immunopharmacology

Volumn 3, Issue 10-11, 2003, Pages 1447-1456

  Karrow, N A ^a   Guo, T L ^a   Zhang, L X ^a   McCay, J A ^a   Musgrove, D L ^a   Peachee, V L ^a   Germolec, D R ^b   White Jr , K L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

B6C3F1 mice; Host resistance; Thalidomide

Indexed keywords

CHROMIUM; CHROMIUM 15; THALIDOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM COLONY; CELL LABELING; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; ERYTHROCYTE; EVALUATION; FEMALE; FIBROSARCOMA; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOMODULATION; INOCULATION; LISTERIA MONOCYTOGENES; LIVER; MELANOMA CELL; MONONUCLEAR PHAGOCYTE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PLASMODIUM YOELII; PROTECTION; SPLEEN; STREPTOCOCCUS PNEUMONIA; TUMOR CELL LINE; TUMOR MODEL;

EID: 0042928356     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00143-7     Document Type: Article

References (42)

1. Marriott J.B., Muller G., Dalgleish A.G. Thalidomide as an emerging immuno-therapeutic agent. Immunol. Today. 20:1999;538-540.
2. Duong D.J., Spigel G.T., Moxley R.T., Gaspari A.A. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch. Dermatol. 135:1999;1079-1087.
3. Eisen T., Boshoff C., Mak I., Sapunar F., Vaughan M.M., Pyle L.et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian, and breast cancer. Br. J. Cancer. 82:1999;812-817.
4. Dredge K., Marriott J.B., Todryk S.M., Muller G.W., Chen R., Stirling D.I.et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol. 168:2002;4914-4919.
5. Karrow N.A., McCay J.A., Brown R.D., Musgrove D.L., Pettit D.A., Munson A.E.et al. Thalidomide stimulates splenic antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice. Toxicol. Appl. Pharmacol. 165:2000;237-244.
6. Bradley S.G. Listeria host resistance model. Burleson G.R., Dean J.H., Munson A.E. Methods in immunotoxicology. vol. 2:1995;169-179 Wilet-Liss and Sons, New York.
7. Cheers C., McKenzie I.F., Pavlov H., Waid C., York J. Resistance and susceptibility of mice to bacterial infection: course of listeriosis in resistant or susceptible mice. Infect. Immun. 19:1978;763-770.
8. McCay J.A. Syngeneic tumor cell models: B16F10 and PYB6. Burleson G.R., Dean J.H., Munson A.E. Methods in immunotoxicology. vol. 2:1995;143-157 Wilet-Liss and Sons, New York.
9. Luebke R.W. Assessment of host resistance to infection with rodent malaria. Burleson G.R., Dean J.H., Munson A.E. Methods in immunotoxicology. vol. 2:1995;221-242 Wilet-Liss and Sons, New York.
10. White K.L. Jr., Lysy H.H., McCay J.A., Anderson A.C. Modulation of serum complement levels following exposure to polychlorinated dibenzo-p-dioxins. Toxicol. Appl. Pharmacol. 84:1986;209-219.
11. White K.L. Jr., Krasula R.W., Munson A.E., Holsapple M.P. Effects of hydroxyethylstarch (Hespan®), a plasma expander, on the functional activity of the reticuloendothelial system. Comparison with human serum albumin and pyran copolymer. Drug Chem. Toxicol. 9:1986;305-322.
12. Bartlett M.S. Sub-sampling for attributes. J. R. Stat. Soc. Suppl. 4:1937;131.
13. Kruskal W.H., Wallis W.A. Use of ranks in one-criterion variance analysis. J. Am. Stat. Assoc. 47:1952;583-621.
14. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50:1955;1096-1121.
15. Wilson K.V. A distribution free test of analysis of variance hypothesis. Psychol. Bull. 53:1956;96-101.
16. Gross A.J., Clark V.A. Gehan-Wilcoxon test. Gross A.J., Clark V.A. Survival distribution: reliability applications in biomedical sciences. 1975;120-123 Wiley, New York.
17. Hollander M., Wolfe D.A. Hollander M., Wolfe D.A. Jonckheere's test: non-parameteric statistics methods. 1975;120-123 Wiley, New York.
18. Fisher-Irwin exact test. Bhattacharyya G.K., Johnson R.A. Statistical concepts and methods. 1977;441-444 Wiley, New York.
19. Shen H., Tato C.M., Fan X. Listeria monocytogenes as a probe to study cell-mediated immunity. Curr. Opin. Immunol. 10:1998;450-458.
20. Choudhury H.R., Sheikh N.A., Bancroft G.J., Katz D.R., De Souza J.B. Early nonspecific immune responses and immunity to blood-stage nonlethal Plasmodium yoelii malaria. Infect. Immun. 68:2000;6127-6132.
21. Conlan J.W. Early pathogenesis of Listeria monocytogenes infection in the mouse spleen. J. Med. Microbiol. 44:1996;295-302.
22. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173:1991;699-703.
23. Rakhmilevich A.L. Neutrophils are essential for resolution of primary and secondary infection with Listeria monocytogenes. J. Leukoc. Biol. 57:1995;827-831.
24. Czuprynski C.J., Brown J.F., Wagner R.D., Steinberg H. Administration of antigranulocyte monoclonal antibody RB6-8C5 prevents expression of acquired resistance to Listeria monocytogenes infection in previously immunized mice. Infect. Immun. 62:1994;5161-5163.
25. Rogers H.W., Unanue E.R. Neutrophils are involved in acute, nonspecific resistance to Listeria monocytogenes in mice. Infect. Immun. 61:1993;5090-5096.
26. Nielsen H., Valerius N.H. Thalidomide enhances superoxide anion release from human polymorphonuclear and mononuclear leukocytes. Acta Pathol. Microbiol. Immunol. Scand. 94:1986;233-237.
27. Dunzendorfer S., Schratzberger P., Reinisch N., Kahler C.M., Wiedermann C.J. Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine- and endotoxin-activated endothelium. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;529-535.
28. Maurice P.D., Barkley A.S., Allen B.R. The effect of thalidomide on arachidonic acid metabolism in human polymorphonuclear leukocytes and platelets. Br. J. Dermatol. 115:1986;677-680.
29. Jorizzo J.L., Schmalstieg F.C., Solomon A.R. Jr., Cavallo T., Taylor R.S. III, Rudloff H.B.et al. Thalidomide effects in Behcet's syndrome and pustular vasculitis. Arch. Intern. Med. 146:1986;878-881.
30. Carneiro-Filho B.A., Souza M.L., Lima A.A., Ribeiro R.A. The effect of tumour necrosis factor (TNF) inhibitors in Clostridium difficile toxin-induced paw oedema and neutrophil migration. Pharmacol. Toxicol. 88:2001;313-318.
31. Barnhill R.L., Doll N.J., Millikan L.E., Hastings R.C. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J. Am. Acad. Dermatol. 11:1984;814-819.
32. Faure M., Thivolet J., Gaucherand M. Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch. Dermatol. Res. 269:1980;275-280.
33. Juffermans N.P., Verbon A., Schultz M.J., Hack C.E., van Deventer S.J., Speelman P.et al. Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens. Antimicrob. Agents Chemother. 45:2001;1547-1549.
34. Makovic S.N., Murasko D.M. Role of natural killer and T-cells in interferon-induced inhibition of spontaneous metastases of the B16F10L murine melanoma. Cancer Res. 51:1991;1124-1128.
35. Loveless S.E., Munson A.E. Maleic vinyl ether activation of murine macrophages against lung-metastasizing tumors. Cancer Res. 41:1981;3901-3906.
36. Murray M.J., Kerkvliet N.I., Ward E.C., Dean J.H. Models for the evaluation of tumor resistance following chemical or drug exposure. Dean J.H., Luster M.I., Munson A.E., Amos H. Immunotoxicology and immunopharmacology. 1985;113-122 Raven Press, New York.
37. Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J. et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. 163:1999;380-386.
38. + subset. J. Exp. Med. 187:1998;1885-1892.
39. Haslett P., Hempstead M., Seidman C., Diakun J., Vasquez D., Freedman V.H.et al. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res. Hum. Retrovir. 13:1997;1047-1054.
40. Bar-Yehuda S., Farbstein T., Barer F., Ohana G., Fishman P. Oral administration of muscle derived small molecules inhibits tumor spread while promoting normal cell growth in mice. Clin. Exp. Metastasis. 17:1999;531-535.
41. Noffz G., Qin Z., Kopf M., Blankenstein T. Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors. J. Immunol. 160:1998;345-350.
42. Glaves D. Role of polymorphonuclear leukocytes in the pulmonary clearance of arrested cancer cells. Invasion Metastasis. 3:1983;160-173.